ARS Pharmaceuticals, Inc. (SPRY) — Total Liabilities
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $213.39M | +126.2% |
| 2024 | $94.36M | +3786.1% |
| 2023 | $2.43M | -71.6% |
| 2022 | $8.55M | -48.7% |
| 2021 | $16.68M | +39.8% |
| 2020 | $11.93M | — |
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $213.39M | +126.2% |
| 2024 | $94.36M | +3786.1% |
| 2023 | $2.43M | -71.6% |
| 2022 | $8.55M | -48.7% |
| 2021 | $16.68M | +39.8% |
| 2020 | $11.93M | — |